Giostar Mexico’s Post

Organoid and scaffold, important component jn regenerative medicine

Alzheimer's Stem Cell Trial Shows Promising Early Results ✦ https://lnkd.in/g-bCtkhg Regeneration Biomedical's Phase 1 trial of adipose-derived stem cell therapy in Alzheimer's patients showed reduced p-Tau and amyloid-beta levels. Cognitive improvements were observed in two of three patients, with increased MMSE scores, signaling a potential for reversing disease processes. https://lnkd.in/g-bCtkhg #astronomy #space #physics

🌟 Inner Ear Organoids: Exciting in vitro model development showcased at the global Stem Cell Event last week in Hambourg 🌟 Last week at ISSCR, Sylvie Pucheu, Léa Jaillot, Ezeddine Harmouch and Azel Z. from LBN Montpellier University presented their recent work on an Efficient Embryoid-based Method to Improve Generation of Otic Vesicles from Human Induced Pluripotent Stem Cells. This 3D in vitro strategy aims to better understand the mechanisms of human otic development and test novel regenerative therapies to combat hearing loss and balance impairments. 🔬 Innovation: The research team adapted a protocol to improve embryoid body-based otic induction from hiPSCs, preserving the integrity and viability of cells forming the otic embryoid bodies (OEBs) and otic vesicle-like structures. Using a Sox2-GFP reporter hiPSC line, we tracked the progression from pluripotency to otic progenitors, showing robust otic induction and improved vesicle generation between days 11-60 of cell cultures. This is a great milestone for the OrgaEar project directed by Professor Azel Zine, that we conduct in collaboration with the University of Montpellier and the support of SATT AxLR. #Organoids #Innovation #StemCells #InVitroModels #TherapiesDevelopment #InnerEarPathologies #ISSCR2024 #HearingResearch #RegenerativeMedicine

👁️ A USC-backed startup has been granted $12.4 million by the California Institute for Regenerative Medicine (CIRM) to conduct a phase 2b clinical trial for an innovative stem cell patch designed to treat advanced dry age-related macular degeneration. 👉 Learn more about this groundbreaking development led by USC researcher Mark Humayun in this article from Modern Retina by David Hutton #AMD #Ophthalmology #HealthcareInnovation #EyeHealth #EyeSurgery #Biotech #Medtech #Lifescience

Can stem cell therapy be the key to stroke recovery? Pardes Habib’s NPIL Neuroimaging Pilot Grant project explores using human neural stem cells (hNSCs) to treat chronic ischemic stroke in rats. This study employs advanced MRI techniques to map microstructural and metabolic changes in the brain. Supported by the Neurosciences Preclinical Imaging Lab (NPIL) at Wu Tsai Neuro, this research aims to identify biomarkers and enhance treatments for future clinical trials. Dive into the research here ➡️ https://lnkd.in/gmDzmD_u

▸ Enhancing understanding of pathological mechanisms in auditory deficiencies. ▸ Facilitating testing of new therapies, including cellular and gene therapies, and medications. ▸ Replacing of animal testing with in vitro models designed to mimic the human inner ear. ▸ Acceleration of therapy development. ▸ Reducing reliance on animal experimentation.   This is what we want to tackle at Cilcare with OrgaEar, a pivotal advancement in audiology research, blending technological innovation with ethical scientific practices. It’s important to know that genetic factors contribute to about 60% of sensorineural hearing loss cases, with over 400 genes implicated. The challenge in developing effective treatments is substantial.   Our collaborations with prestigious institutions like University of Montpellier and Mass. Eye and Ear underscore our dedication to advancing regenerative medicine and addressing its challenges. This post is an opportunity to highlight some of the major players in the field, including Rinri Therapeutics, Lineage Cell Therapeutics, Mogrify, Akouos (Lilly), Regeneron, Sensorion, Refresh Gen Tx, Rescue Hearing Inc./ Myrtelle, Skylark Bio, and Aposense. We anticipate many more to come, as major pharmaceutical companies also enter this exciting field 😉.    #TherapyDevelopment #EthicalScience #Genetics #HearingLoss

📌 Save the date for an upcoming CONNECT Symposium 2025! This one-day symposium will explore advances in bioengineering, in vitro blood-brain barrier (BBB) modeling, and brain organoids. CONNECT is a multi-disciplinary consortium working on the development of organoids and in complex vitro BBB models using pluripotent human stem cells. These new models aim to fill a critical gap, providing a unique research platform to better help identify new compounds against various, currently incurable, nervous system disorders. InnoSer is happy to be part of this research consortium dedicated to advancing the translation of CNS-targeting drugs from the lab to the clinic. 👉 Reach out to our team to inquire more about InnoSer's research activities that may be relevant for your research: https://lnkd.in/eHH4bmZT.

🔬🌿 Unlocking the Power of Stem Cells: A Journey Through Potency and Promise 🧬 In our latest blog post, we dive deep into the world of stem cells, exploring the different types and their potency. From the pluripotent embryonic stem cells (ESCs) to the multipotent adult stem cells (ASCs) and the groundbreaking induced pluripotent stem cells (iPSCs), we unravel the unique properties and potential applications of each type. 🔍 We also shine a spotlight on mesenchymal stem cells (MSCs), a promising subtype of ASCs that have garnered significant attention in regenerative medicine. 💪 Companies like 23 Century Lifecord in Malaysia are at the forefront of harnessing the power of MSCs derived from umbilical cord blood to develop innovative treatments for various conditions. 🇲🇾 But which stem cell type holds the most promise? 🤔 We compare the potency and characteristics of ESCs, ASCs, and iPSCs, discussing the advantages and limitations of each. While ESCs offer the broadest differentiation potential, ethical concerns and the risk of teratoma formation have limited their clinical applications. ASCs, particularly MSCs, provide a more accessible and ethically acceptable option, with the ability to target specific tissues and exert immunomodulatory effects. iPSCs bridge the gap between ESCs and ASCs, enabling patient-specific therapies and disease modeling, but their clinical translation is still in the early stages. The future of stem cell-based therapies is bright, and by staying informed about the latest developments and supporting ongoing research efforts, we can contribute to the advancement of these life-changing technologies. 🌟 Read our blog post now to uncover the fascinating world of stem cells and learn how companies like 23 Century Lifecord are pushing the boundaries of regenerative medicine! 🔗 Link in the comments below. 👇 https://lnkd.in/gSw2ACG2 #StemCells #RegenerativeMedicine #CellTherapy #MedicalResearch #23CenturyLifecord #Biotechnology #Science #Innovation

Elevating stem cell potential with advanced cell models. Stem cells hold incredible promise for both research and therapeutic development. A key breakthrough is the creation of advanced cell models, like organoids, which closely replicate human physiology. These models are invaluable for studying complex biological processes and disease mechanisms. However, working with stem cells comes with its challenges. They require meticulous care and are expensive to maintain, demanding precise culture conditions and constant monitoring to retain their unique ability to differentiate into various cell types. In our latest eBook, learn more about how advanced cell models are pushing the boundaries of stem cell research. We also provide insights into effective strategies for culturing, maintaining, and characterizing stem cells to ensure the highest quality models. Download now: https://ow.ly/OM4s50TcmO7 #StemCells #AdvancedCellModels #Organoids #CellSelection

Accelerating neovascularization in patients with chronic ischemia is feasible prior to invasive arterial interventions. Learn more about it at https://t.ly/Mfz7n